Nilotinib and Osimertinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Potential additive QT prolongation may increase ventricular arrhythmia risk.
Clinical significance and safety
Both nilotinib and osimertinib have QT-prolongation warnings in their product information. TASIGNA advises avoiding concomitant QT-prolonging medicines; this is a pharmacodynamic risk warning, not evidence from a dedicated study of this exact pair. Any overlap requires an oncology-led review of necessity, ECGs and electrolytes.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.